Importer of Controlled Substances Application: Sharp Clinical Services, LLC
Published Date: 2/2/2026
Notice
Summary
Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, including some Schedule I drugs like Gamma Hydroxybutyric Acid and MDMA. This affects companies involved in drug manufacturing and regulation, who can comment or request a hearing by March 4, 2026. No fees or immediate changes yet, but this step could impact drug supply chains soon.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Import Use Limited; No Commercial Finished Drugs
The company plans to import the listed substances for distribution and clinical trials only; the registration would not authorize any other activities for these drug codes. The authorization explicitly will not extend to importing Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale.
New Importer Seeks Schedule I Registration
Sharp Clinical Services, LLC applied on January 9, 2026 to be registered as an importer of four Schedule I controlled substances: Gamma Hydroxybutyric Acid (code 2010), 3,4‑Methylenedioxy‑methamphetamine (MDMA, code 7405), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431), and Psilocybin (code 7437). Registered bulk manufacturers and other interested parties may submit comments or request a hearing on the application on or before March 4, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-01943 — National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a meeting on June 2, 2026, that’s partly open to the public and partly closed to protect private info about grant applications. Researchers and the public can join the open session online or in person, while the closed session will review important funding decisions. This meeting helps decide who gets money to study arthritis and related diseases, shaping future research and treatments.
Next: 2026-01945 — Marine Mammals; Proposed Incidental Harassment Authorization for Polar Bears in the Beaufort Sea and Arctic Ocean; Ice Exercise Activities by the U.S. Navy
The U.S. Fish and Wildlife Service is considering letting the Navy do some temporary ice camp and training activities in the Arctic from February to April 2026. These activities might disturb up to six polar bears but won’t hurt them. The public can share their thoughts by March 4, 2026, before a final decision is made.